HER2 overexpression in metastatic breast cancer: development of therapies

被引：0

作者：

Pivot, X. ^{[1
]}

Jary, M. ^{[1
]}

Dobi, E. ^{[1
]}

Bazan, F. ^{[1
]}

Chaigneau, L. ^{[1
]}

Cals, L. ^{[1
]}

Almotlak, H. ^{[1
]}

Montcuquet, P. ^{[1
]}

Meneveau, N. ^{[1
]}

Villanueva, C. ^{[1
]}

机构：

[1] CHU Besancon, Med Oncol Serv, F-25000 Besancon, France

来源：

ONCOLOGIE | 2012年 / 14卷 / 01期

关键词：

To be confirmed metastatic breast cancer; HER2; New therapies; Monoclonal antibodies; PHASE-II TRIAL; TRASTUZUMAB; PLUS; CAPECITABINE; PERTUZUMAB; LAPATINIB; DOCETAXEL; EFFICACY; SAFETY;

D O I：

10.1007/s10269-011-2106-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Currently, the standard first-line treatment for patients with HER2 overexpression in metastatic breast cancer is trastuzumab in combination with taxane. Where progress of the disease is seen with trastuzumab, lapatinib in combination with capecitabine, or changing to treatment using trastuzumab with capecitabine has demonstrated interesting results. With the aim of further improving results for these patients, a number of new therapies are being evaluated. Combining trastuzumab with other monoclonal antibodies such as pertuzumab and bevacizumab, or with cytotoxins like TDM1, or with anti-mTORs such as everolimus, which targets other signalling pathways used in cell proliferation and survival, has shown promising results and will soon be part of our range of therapies. To cite this journal: Oncologie 14 (2012).

引用

页码：37 / 40

页数：4

共 50 条

[21] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
Zidan, J.
Mzalbat, R.
Shnaider, J.
Sharabi, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[22] Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
Fabi, A
Ferretti, G
Salesi, N
Papaldo, P
Carlini, P
Ciccarese, M
Di Cocco, B
Cecere, F
Nardoni, C
Felici, A
Cognetti, F
ANNALS OF ONCOLOGY, 2005, 16 (03) : 516 - 517
[23] Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC).
Penault-Llorca, F
Vincent-Salomon, A
Mathieu, MC
Trillet-Lenoir, V
Khayat, D
Marty, M
Perrin, J
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 69S - 69S
[24] Long-term survival of patients with HER2 metastatic breast cancer treated by targeted therapies
Fiteni, F.
Villanueva, C.
Bazan, F.
Chaigneau, L.
Cals, L.
Dobi, E.
Montcuquet, P.
Nerich, V.
Limat, S.
Pivot, X.
CANCER RESEARCH, 2012, 72
[25] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Horimoto, Yoshiya
Ishizuka, Yumiko
Ueki, Yuko
Higuchi, Toru
Arakawa, Atsushi
Saito, Mitsue
BMC CANCER, 2022, 22 (01)
[26] Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
Rassy, Elie
Rached, Layal
Pistilli, Barbara
BREAST, 2022, 66 : 217 - 226
[27] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Yoshiya Horimoto
Yumiko Ishizuka
Yuko Ueki
Toru Higuchi
Atsushi Arakawa
Mitsue Saito
BMC Cancer, 22
[28] Dual HER2 inhibition and paclitaxel in metastatic breast cancer
Brower, Vicki
LANCET ONCOLOGY, 2015, 16 (02): : E57 - E57
[29] HER2 overexpression and cancer targeting
Wang, SC
Hung, MC
SEMINARS IN ONCOLOGY, 2001, 28 (05) : 115 - 124
[30] Precision medicine for HER2 negative metastatic breast cancer
Hara, Fumikata
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →